SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nifty Pharma sinks as Trump readies 100% drug tariffs

… more than 5%. Glenmark Pharmaceuticals , Aurobindo Pharma , Sun Pharmaceutical Industries, and Ipca Laboratories … to 50% of all generic drugs consumed in the US, making the … with the White House. For Indian pharmaceutical companies, the stakes remain high. …

Brief India: HDFC Bank (HDFCB IN) Tactical Outlook: Hold or Sell? and more

In this briefing: HDFC Bank (HDFCB IN) Tactical Outlook: Hold or Sell? Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts 1. HDFC Bank (HDFCB IN) Tactical Outlook: Hold or Sell? HDFC Bank (HDFCB IN) has been losing steam since last summer. In the last few months the stock started to sell-off, but it did not lose more than 10%. A recent pullback was flagged as oversold by our quantitative model, last Friday. Then the stock started to rally this week. We think the current rally may be a sell opportunity, possibly taking advantage of the stock recent volatility. Selling setups identified by our model are discussed in this insight. 2. Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market The shift to "Agentic AI" could propel the global economy to $500 trillion , provided companies overhaul business architectures to bridge the current gap between tech progress and realized value.

Brief India: Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market and more

In this briefing: Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate 1. Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market The shift to "Agentic AI" could propel the global economy to $500 trillion , provided companies overhaul business architectures to bridge the current gap between tech progress and realized value. Through the Topaz Fabric , Infosys is deploying over 600 specialized agents and small language models (SLMs) to help 90% of their top clients move from pilots to production. Success requires navigating the " Brownfield " productivity gap, where legacy systems and data silos currently consume 60-80% of IT budgets , hindering the deployment of high-impact AI solutions. 2.

Brief India: Exencial Indutry Tiding and more

In this briefing: Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 1. Exencial Indutry Tiding Bajaj Hindusthan Sugar's sales decline by 6.7% in December 2025 quarter Man-Made filaments & fibres industry's sales grow by 15.2% in December 2025 quarter Personal & home care products industry's sales grow by 5.4% in December 2025 quarter 2. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations.

Brief Growth Ideas: Primer: CSL (CSL AT) - Feb 2026 and more

In this briefing: Primer: CSL (CSL AT) - Feb 2026 Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Oil futures: Crude lower as Iran says 'understanding' reached with US HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts 1. Primer: CSL (CSL AT) - Feb 2026 CSL is a global biotechnology leader with a dominant position in plasma-derived therapies ( CSL Behring) and a significant presence in the influenza vaccine market ( CSL Seqirus). The recent acquisition of Vifor Pharma has diversified CSL's portfolio into the attractive markets of nephrology and iron deficiency, providing a new avenue for growth. While facing near-term headwinds from policy changes, competitive pressures, and a recent CEO transition, the company's long-term outlook is supported by a strong R&D pipeline, recovering plasma collections, and strategic cost-saving initiatives. This content is AI-generated and displayed for general informational purposes only.

Brief India: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform and more

In this briefing: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 Ahluwalia Contracts India Ltd - Misses Estimates on Slower Execution; Retain BUY 1. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations. In this note, we talk about the positive aspects about the company’s historical performance. 2. HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts IPCA Laboratories: EBITDA growth of 22% YoY was driven by 7% YoY sales growth (India grew 12% YoY), higher GM (+226 bps YoY at 72.5%), and cost controls (staff/SG&A +10%/+4% YoY), causing the margin to expand to 22.7% (+284 bps YoY) IPCA expects (1) overall business to see 10-11% growth in the near term (IPCA standalone growth at 10-12% and Unichem business at 8-9%) (2) India business to outperform IPM growth in the next few years, led by sustained momentum in key therapies (pain, CVS, anti-diabetics, CNS, and derma), looking to in-licensing Semaglutide to participate in India GLP-1 market Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform and more

In this briefing: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Oil futures: Crude lower as Iran says 'understanding' reached with US HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook 1. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations. In this note, we talk about the positive aspects about the company’s historical performance. 2. Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Shenzhen Vmax New Energy Lt is a key supplier of power electronics for new energy vehicles (NEVs), specializing in on-board chargers and DC/DC converters.

Brief Growth Ideas: Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 and more

In this briefing: Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Oil futures: Crude lower as Iran says 'understanding' reached with US HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate 1. Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Shenzhen Vmax New Energy Lt is a key supplier of power electronics for new energy vehicles (NEVs), specializing in on-board chargers and DC/DC converters. The company is well-positioned to benefit from the continued growth of the global NEV market, particularly in China, its primary market. Financial performance has shown strong revenue growth, though profitability metrics warrant monitoring amidst a competitive landscape. This content is AI-generated and displayed for general informational purposes only. Please verify independently before use. 2.

Brief India: HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts and more

In this briefing: HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 Ahluwalia Contracts India Ltd - Misses Estimates on Slower Execution; Retain BUY Fortis Healthcare Ltd - Healthy Core Performance; Expansion to Drive Next Leg 1. HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts IPCA Laboratories: EBITDA growth of 22% YoY was driven by 7% YoY sales growth (India grew 12% YoY), higher GM (+226 bps YoY at 72.5%), and cost controls (staff/SG&A +10%/+4% YoY), causing the margin to expand to 22.7% (+284 bps YoY) IPCA expects (1) overall business to see 10-11% growth in the near term (IPCA standalone growth at 10-12% and Unichem business at 8-9%) (2) India business to outperform IPM growth in the next few years, led by sustained momentum in key therapies (pain, CVS, anti-diabetics, CNS, and derma), looking to in-licensing Semaglutide to participate in India GLP-1 market Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Smartkarma | HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts

» Smartkarma / by HDFC Securities / Thematic (Sector/Industry) IPCA Laboratories: EBITDA growth of 22% YoY was driven by 7% YoY sales growth (India grew 12% YoY), higher GM (+226 bps YoY at 72.5%), and cost controls (staff/SG&A +10%/+4% YoY), causing the margin to expand to 22.7% (+284 bps YoY) IPCA expects (1) overall business to see 10-11% growth in the near term (IPCA standalone growth at 10-12% and Unichem business at 8-9%) (2) India business to outperform IPM growth in the next few years, led by sustained momentum in key therapies (pain, CVS, anti-diabetics, CNS, and derma), looking to in-licensing Semaglutide to participate in India GLP-1 market Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. » Get straight to the source on Smartkarma.

Ipca Laboratories Ltd. engages in the manufacturing, marketing, research, and development of pharmaceutical products. Its products include Hydroxychloroquine Sulphate, Artemether and Lumefantrine and Acceclofenac and its combinations. The company was founded on October 19, 1949 and is headquartered in Mumbai, India.

Ipca Laboratories Ltd.

Medium-Term Trade Ideas: SEBI RA Flags Tata Motors, IPCA Labs, Atul Auto And 4 More Stocks For Breakout Ahead

Equity

Neutral Sentiment

Seven stocks have made their way to SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Vinaytaparia">Vinay Taparia</a>’s breakout watchlist, driven by strong chart patterns, healthy volumes. From Tata Motors to Trident, he sees the potential for upside, provide key support levels are not breached.&nbsp;Let’s take a look at his recommendations:Tata Motors<a href="https://stocktwits.com/symbol/TATAMOTORS.NSE">Tata Motors</a> has given a good breakout from a small range. The stock is expected to move to ₹745-₹810 over the next six to nine months. But a close below ₹667 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622322109</stembedurl>IPCA Laboratories<a href="https://stocktwits.com/symbol/IPCALAB.NSE">IPCA Labs</a> has experienced a notable breakout on its daily chart, accompanied by high volumes. The Relative Strength Index (RSI) is also above 70. The stock can potentially move to the ₹1,750 level within the next six months; however, a close below ₹1,440 would negate this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622324172</stembedurl>Fertilisers And Chemicals Travancore (FACT)<a href="https://stocktwits.com/symbol/FACT.NSE">FACT</a> has given a good breakout on the daily chart. It can move to ₹1,040-₹1,100 in the next six to nine months, but a close below ₹940 invalidates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622317505</stembedurl>IVP Limited<a href="https://stocktwits.com/symbol/IVP.NSE">IVP</a> has seen a notable breakout on the daily chart, accompanied by strong volume. It has also taken support at the upward-moving trendline. The stock is above its 200 and 50-day Exponential Moving Averages (EMAs). The RSI is also above 60.&nbsp;IVP can move to ₹220-₹235 level in the next six months. A close below ₹185 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622317654</stembedurl>HLE Glascoat&nbsp;<a href="https://stocktwits.com/symbol/HLEGLAS.NSE">HLE Glascoat</a> has given a strong breakout on its daily chart, accompanied by high volumes. The RSI is also above 60. The stock is expected to move towards the ₹480-₹515 level over the next six months; however, a close below ₹415 would negate this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622317804</stembedurl>Atul Auto&nbsp;<a href="https://stocktwits.com/symbol/ATULAUTO.NSE">Atul Auto</a> has formed a morning star pattern with good volumes at trendline support. It can move to ₹505-₹520 in the next 6 months. A close below ₹444 invalidates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622317928</stembedurl>Trident&nbsp;<a href="https://stocktwits.com/symbol/TRIDENT.NSE">Trident</a> shares are on the verge of a breakout. The stock can move to ₹39 level in nine to twelve months. A close below ₹29 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/622399441</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Financial market volatility on digital interface with fluctuating trading data real-time stock market analysis and investment trends. (Stock picture/Getty Images)

FACT, IVP, and others may see 15–25% upside over 6–9 months if key support levels hold, said the analyst.

Current Price	1,904.40
Prev Close	1,905.00
Open	1,900.10
Dividend Yield	0.37%
50-Day Moving Average	1,927.00
Beta	N/A
Avg. Volume	225,514.73
PE Ratio	34.37

52-Week High	2,038.00
52-Week Low	1,305.00
Market Capitalization	491.69B
EPS (Annual)	44.98
Price to Book	5.55
Revenue Per Employee	4.07M

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPCALAB.NSE Fundamentals